Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Equity (2022 - 2025)

Historic Return on Equity for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.53%.

  • ARS Pharmaceuticals' Return on Equity fell 2400.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 2400.0%. This contributed to the annual value of 0.03% for FY2024, which is 2500.0% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Return on Equity of 0.53% as of Q3 2025, which was down 2400.0% from 0.28% recorded in Q2 2025.
  • ARS Pharmaceuticals' Return on Equity's 5-year high stood at 0.01% during Q4 2024, with a 5-year trough of 0.53% in Q3 2025.
  • For the 4-year period, ARS Pharmaceuticals' Return on Equity averaged around 0.2%, with its median value being 0.24% (2023).
  • In the last 5 years, ARS Pharmaceuticals' Return on Equity soared by 2800bps in 2024 and then tumbled by -2400bps in 2025.
  • ARS Pharmaceuticals' Return on Equity (Quarter) stood at 0.13% in 2022, then plummeted by -119bps to 0.29% in 2023, then surged by 95bps to 0.01% in 2024, then plummeted by -3865bps to 0.53% in 2025.
  • Its Return on Equity stands at 0.53% for Q3 2025, versus 0.28% for Q2 2025 and 0.11% for Q1 2025.